Company profile
Neurocrine Biosciences, Inc.
Pipeline17 assets
- direclidineM4 / Small Molecule / PsychiatrySchizophreniaPhase 3Bipolar ManiaPhase 2
- NBI-570M1/M4 / Small Molecule / PsychiatrySchizophreniaPhase 2
- osavampatorAMPA / Small Molecule / PsychiatryMajor Depressive DisorderPhase 3
- NBI-986M4 / Small Molecule / NeurologyMovement DisordersPhase 1
- NBI-890VMAT2 / Small Molecule / PsychiatryTardive DyskinesiaPhase 2
- NBI-569M1/M4 / Small Molecule / PsychiatryAlzheimer's PsychosisPhase 1
- NBI-567M1 / Small Molecule / NeurologyAlzheimer's CognitionPhase 1
- NBI-355Nav1.2/1.6 / Small Molecule / NeurologyEpilepsyPhase 1
- NBIP-1435CRF1 / Peptide / EndocrinologyClassic Congenital Adrenal HyperplasiaPhase 1
- NBIP-2118CRF2 / Peptide / EndocrinologyObesityPhase 1
- NBIP-1968TG + NBIP-2118 Combo / Peptide / EndocrinologyObesityPhase 4
- NBIB-223Frataxin / Gene Therapy / NeurologyFriedreich's AtaxiaPhase 4
- NBI-675VMAT2 / Small Molecule / PsychiatryCNS IndicationsPhase 1
- NBI-188CRF1 / Small Molecule / EndocrinologyWomen's HealthPhase 4
- NBIM-1748ImmunologyUndisclosedPhase 4
- NBIM-1008ImmunologyUndisclosedPhase 4
- NBIM-1112ImmunologyUndisclosedPhase 1
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.